Sensitivity and specificity of proposed surrogates for nonmutated IgVH gene mutation status
Surrogate for IgVH . | Sensitivity, % . | Specificity, % . | References . |
|---|---|---|---|
| CD38 using 30% cutoff* | 45-85 | 71-100 | Damle et al,7 † Hamblin et al,38 ‡ Krober et al,35 ‡ Crespo et al77 † |
| CD38 using 7% cutoff* | 63-66 | 63-68 | Jelinek et al,36 † Krober et al35 ‡ |
| CD38 using presence of clone* | 80 | 85 | Ghia et al50 † |
| Thymidine kinase* | 76 | 91 | Magnac et al23 ‡ |
| ZAP-70*§ | 89-91 | 95-100 | Wiestner et al,69 ‡ Crespo et al77 † |
Surrogate for IgVH . | Sensitivity, % . | Specificity, % . | References . |
|---|---|---|---|
| CD38 using 30% cutoff* | 45-85 | 71-100 | Damle et al,7 † Hamblin et al,38 ‡ Krober et al,35 ‡ Crespo et al77 † |
| CD38 using 7% cutoff* | 63-66 | 63-68 | Jelinek et al,36 † Krober et al35 ‡ |
| CD38 using presence of clone* | 80 | 85 | Ghia et al50 † |
| Thymidine kinase* | 76 | 91 | Magnac et al23 ‡ |
| ZAP-70*§ | 89-91 | 95-100 | Wiestner et al,69 ‡ Crespo et al77 † |
These markers have all been shown to have prognostic significance independent of their relationship to IgVH gene mutation status.
Sensitivity and specificity as reported in reference text.
Sensitivity and specificity calculated from published data.
The results from Wiestner et al69 are based on ZAP-70 mRNA expression by gene expression profile analysis; results from Crespo et al77 are based on flow cytometry using 20% threshold to classify the patient's expression of ZAP-70. See “Gene expression profile analysis: roadmap to other prognostic markers.”